Seer (NASDAQ:SEER) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Posted by Stanley Muller on Aug 13th, 2026

Seer (NASDAQ:SEER – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04), FiscalAI reports. Seer had a negative return on equity of 26.39% and a negative net margin of 478.05%.The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.55 million.

Here are the key takeaways from Seer’s conference call:

Revenue remained under pressure, with second-quarter revenue of $3.1 million versus $4.1 million a year earlier, due to weak academic and government funding and longer sales cycles. The company posted a $16.9 million net loss.
Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, citing stronger customer discussions, increased consumable pull-through, new commercial leadership, and anticipated population-scale study opportunities in the second half.
Seer reported more than 95 publications, preprints, and reviews supporting the Proteograph platform, while independent studies highlighted its depth, reproducibility, and ability to identify proteins and genetic associations missed by competing assays.
The company ended the quarter with $209.5 million in cash and investments, believes it has sufficient capital to reach cash-flow breakeven, and has repurchased approximately 13.4 million shares, reducing net shares outstanding by about 15%.
Seer completed the first 10,000 samples of its PRECISE-SG100K population study and plans to present preliminary data at HUPO in September, while continuing discussions with potential large-scale cohort partners. Management views these results as a potential catalyst for larger buyback commitments and broader adoption.

Seer Price Performance

SEER opened at $2.14 on Thursday. Seer has a 12 month low of $1.55 and a 12 month high of $2.41. The stock has a market capitalization of $117.66 million, a price-to-earnings ratio of -1.75 and a beta of 1.56. The business has a fifty day moving average price of $1.95 and a 200 day moving average price of $1.88.

Analyst Ratings Changes

Several research analysts have recently commented on SEER shares. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research report on Friday, July 17th. Canaccord Genuity Group started coverage on Seer in a research note on Monday, May 4th. They set a “buy” rating and a $4.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $4.00.

Read Our Latest Stock Analysis on SEER

Hedge Funds Weigh In On Seer

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management LLC increased its holdings in Seer by 15.5% in the second quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock valued at $1,792,000 after buying an additional 112,100 shares during the last quarter. XTX Topco Ltd purchased a new stake in Seer during the 2nd quarter worth about $172,000. Geode Capital Management LLC boosted its position in shares of Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after acquiring an additional 72,265 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock valued at $430,000 after acquiring an additional 63,432 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new position in shares of Seer in the 4th quarter valued at about $116,000. Hedge funds and other institutional investors own 75.20% of the company’s stock.

About Seer

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.